Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor. This approach is promising for patients with hematologic malignancies refractory to chemotherapy. Despite impressive results, too many patients are relapsing. The reasons for the relapse, after the injection of CAR T cells, need to be explored. In this context of newly introduced therapeutics, it is essential to better understand the factors associated with the response to treatment with CAR T Cells, especially the characteristics of the tumor and its microenvironment. The objective of this study is to understand the role of tumor biology, and its microenvironment, in the response to CAR-T Cells therapy in patients with hematologic malignancies
Study Type
OBSERVATIONAL
Enrollment
600
Complete response rate
Time frame: 90 days after (CAR)-T cell therapy initiation
Overall Survival rate
Time frame: 1 year
Objective response rate
Time frame: 30 days
Objective response rate
Time frame: 90 days
Objective response rate
Time frame: 1 year
Objective response rate
Time frame: 2 years
Objective response rate
Time frame: 5 years
Objective response rate
Time frame: 10 years
Progression-free survival
Time frame: at 1 year
Incidence of adverse events
Time frame: at 30 days
Incidence of adverse events
Time frame: at 90 days
Incidence of adverse events
Time frame: at 1 year
Incidence of adverse events
Time frame: at 2 years
Incidence of adverse events
Time frame: at 5 years
Incidence of adverse events
Time frame: at 10 years
Proportion of patients with an admission in intensive care
Time frame: at 30 days
Proportion of patients with an admission in intensive care
Time frame: at 90 days
Severity of neurological toxicities
Severity of neurological toxicities will be assessed by physical, and by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: at 30 days
Severity of neurological toxicities
Severity of neurological toxicities will be assessed by physical examination and by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: at 90 days
Severity of neurological toxicities
Severity of neurological toxicities will be assessed by physical, cognitive examination and by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: at 6 months
Severity of neurological toxicities
Severity of neurological toxicities will be assessed by physical examination and by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: at 2 years
Severity of neurological toxicities
Severity of neurological toxicities will be assessed by physical examination and by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: at 5 years
Severity of neurological toxicities
Severity of neurological toxicities will be assessed by physical examination and by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: at 10 years
Proportion of patients with a cytokine release syndrome
Cytokine release syndrome will be assessed by CTCAE v5.0
Time frame: at baseline
Proportion of patients with a cytokine release syndrome
Cytokine release syndrome will be assessed by CTCAE v5.0
Time frame: at 7 days
Proportion of patients with a cytokine release syndrome
Cytokine release syndrome will be assessed by CTCAE v5.0
Time frame: at 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.